SG11201504164VA - 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST - Google Patents

6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST

Info

Publication number
SG11201504164VA
SG11201504164VA SG11201504164VA SG11201504164VA SG11201504164VA SG 11201504164V A SG11201504164V A SG 11201504164VA SG 11201504164V A SG11201504164V A SG 11201504164VA SG 11201504164V A SG11201504164V A SG 11201504164VA SG 11201504164V A SG11201504164V A SG 11201504164VA
Authority
SG
Singapore
Prior art keywords
tarp
benzothiazol
pyrazol
pyridin
ethoxy
Prior art date
Application number
SG11201504164VA
Other languages
English (en)
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201504164VA publication Critical patent/SG11201504164VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201504164VA 2012-11-27 2013-11-20 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST SG11201504164VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
PCT/US2013/070885 WO2014085153A1 (en) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist

Publications (1)

Publication Number Publication Date
SG11201504164VA true SG11201504164VA (en) 2015-07-30

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504164VA SG11201504164VA (en) 2012-11-27 2013-11-20 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST

Country Status (36)

Country Link
US (1) US8765960B2 (ar)
EP (1) EP2925754B1 (ar)
JP (1) JP6246227B2 (ar)
KR (1) KR101693133B1 (ar)
CN (1) CN104797578B (ar)
AP (1) AP2015008489A0 (ar)
AR (1) AR093527A1 (ar)
AU (1) AU2013352594B2 (ar)
BR (1) BR112015011200A2 (ar)
CA (1) CA2889243C (ar)
CL (1) CL2015001419A1 (ar)
CR (1) CR20150267A (ar)
CY (1) CY1118657T1 (ar)
DK (1) DK2925754T3 (ar)
DO (1) DOP2015000113A (ar)
EA (1) EA026686B1 (ar)
ES (1) ES2618260T3 (ar)
HK (1) HK1209116A1 (ar)
HR (1) HRP20170274T1 (ar)
HU (1) HUE033447T2 (ar)
IL (1) IL238831B (ar)
JO (1) JO3225B1 (ar)
MA (1) MA38126B1 (ar)
MX (1) MX356478B (ar)
MY (1) MY177721A (ar)
PE (1) PE20151728A1 (ar)
PH (1) PH12015501154B1 (ar)
PL (1) PL2925754T3 (ar)
PT (1) PT2925754T (ar)
SG (1) SG11201504164VA (ar)
SI (1) SI2925754T1 (ar)
TN (1) TN2015000200A1 (ar)
TW (2) TW201825484A (ar)
UA (1) UA114345C2 (ar)
WO (1) WO2014085153A1 (ar)
ZA (1) ZA201503733B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
JP6804469B2 (ja) * 2015-04-29 2020-12-23 ヤンセン ファーマシューティカ エヌ．ベー． ベンゾイミダゾロン及びベンゾチアゾロン化合物並びにａｍｐａ受容体調節因子としてのそれらの使用
BR112017023038A2 (pt) 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
AU2016256413B2 (en) 2015-04-29 2020-10-08 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
WO2016176460A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators
EA036903B1 (ru) * 2016-10-26 2021-01-13 Янссен Фармацевтика Нв Соединения конденсированных бициклических пиридинов и их применение в качестве модуляторов ampa-рецептора
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ａｍｐａ拮抗化合物の新規製造法
BRPI0111596B8 (pt) * 2000-06-12 2022-07-26 Eisai Co Ltd Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
EP1828177B1 (en) * 2004-12-17 2008-08-13 Eli Lilly And Company Novel mch receptor antagonists
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
JP2012505198A (ja) * 2008-10-08 2012-03-01 ファイザー・インク Ｃｎｓ障害を治療する際にａｍｐａ調節剤として使用するためのテトラヒドロフラニルスルホンアミド
GEP20135992B (en) * 2009-01-12 2013-12-25 Icagen Inc Sulfonamide derivatives
AU2011261586B2 (en) * 2010-06-01 2015-08-27 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
WO2012137982A2 (en) * 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物

Also Published As

Publication number Publication date
BR112015011200A2 (pt) 2017-07-11
TW201825484A (zh) 2018-07-16
MX2015006697A (es) 2015-08-05
TN2015000200A1 (en) 2016-10-03
TW201434834A (zh) 2014-09-16
MA38126A1 (fr) 2017-03-31
CA2889243C (en) 2017-06-13
MA38126B1 (fr) 2017-11-30
MX356478B (es) 2018-05-30
ZA201503733B (en) 2017-09-27
UA114345C2 (uk) 2017-05-25
CL2015001419A1 (es) 2015-10-02
ES2618260T3 (es) 2017-06-21
JP2016501219A (ja) 2016-01-18
KR101693133B1 (ko) 2017-01-04
JP6246227B2 (ja) 2017-12-13
WO2014085153A1 (en) 2014-06-05
IL238831B (en) 2018-08-30
TWI618705B (zh) 2018-03-21
EP2925754B1 (en) 2016-12-28
EA201590823A1 (ru) 2015-08-31
CN104797578B (zh) 2016-11-23
PT2925754T (pt) 2017-02-27
US8765960B2 (en) 2014-07-01
HUE033447T2 (en) 2017-11-28
CR20150267A (es) 2015-09-16
SI2925754T1 (sl) 2017-02-28
AU2013352594B2 (en) 2016-02-18
PH12015501154A1 (en) 2015-08-10
EA026686B1 (ru) 2017-05-31
PH12015501154B1 (en) 2015-08-10
EP2925754A1 (en) 2015-10-07
AR093527A1 (es) 2015-06-10
MY177721A (en) 2020-09-23
CA2889243A1 (en) 2014-06-05
HK1209116A1 (en) 2016-03-24
JO3225B1 (ar) 2018-03-08
PL2925754T3 (pl) 2017-07-31
US20140148441A1 (en) 2014-05-29
KR20150070401A (ko) 2015-06-24
HRP20170274T1 (hr) 2017-04-07
WO2014085153A8 (en) 2014-07-31
DK2925754T3 (en) 2017-02-20
DOP2015000113A (es) 2015-06-15
PE20151728A1 (es) 2015-12-02
CN104797578A (zh) 2015-07-22
AU2013352594A1 (en) 2015-06-04
CY1118657T1 (el) 2017-07-12
IL238831A0 (en) 2015-06-30
AP2015008489A0 (en) 2015-05-31

Similar Documents

Publication Publication Date Title
SG11201504164VA (en) 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1&lt;i&gt;H&lt;/i&gt;-PYRAZOL-3-YL}-ETHYL)-3&lt;i&gt;H&lt;/i&gt;-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST
BRPI1012108A2 (pt) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrila como inibidores de jak
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
ZA201106117B (en) Graphical user interface for search request management
IL205665A0 (en) Heteroaryl derivatives as orexin receptor antagonists
IL212436A0 (en) Isonicotinamide orexin receptor antagonists
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
PL2552906T3 (pl) Antagonista receptorów CGRP
EP2386546A4 (en) NEW PYRAZOL-3-CARBOXYLIC ACID AMID DERIVATIVITY WITH 5-HT2B RECEPTOR ANTAGONIZING EFFECT
ZA201604501B (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
EP2370425A4 (en) IMIDAZOLE DERIVATIVES CONDENSED AS TRPV3 ANTAGONISTS
IL207577A0 (en) Pyrrolidine ether derivatives as nk3 receptor antagonists
IL217759A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
IL223060A0 (en) Nicotinic receptor non-competitive antagonists
IL207700A0 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists
IL213763A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
HK1165418A1 (en) Azetidines as histamine h3 receptor antagonists h3
IL218170A0 (en) [1,4]-benzodiazepines as vasopressin v2 receptor antagonists
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
EP2846800A4 (en) HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS